COM-701 is under clinical development by Compugen and currently in Phase II for Hypopharyngeal Cancer. According to GlobalData, Phase II drugs for Hypopharyngeal Cancer does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the COM-701 LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
COM-701 overview
COM-701 is under development for the treatment of solid tumors including metastatic breast cancer, colorectal cancer, non-small cell lung cancer, ovarian cancer, triple negative breast cancer, multiple myeloma, invasive ductal carcinoma, PD1 refractory or relapsing head and neck squamous cell carcinoma including oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal, non-small cell lung cancer, colorectal cancer, endometrial cancer, primary peritoneal cancer and fallopian tube cancer. The drug candidate is a high affinity humanized IgG4 mAb. It is administered intravenously. It acts by targeting CGEN-15029/PVRIG, a B7/CD28 like immune checkpoint protein. The drug candidate is developed based on antibody therapeutic targets discovery platform and protein family members discovery platform.
Compugen overview
Compugen is a clinical-stage drug discovery and development company that develops medicines for immuno-oncology and autoimmune diseases. The company’s pipeline products include COM701 and PVRIG, BAY 1905254, COM902 and TIGIT. Its drug development process includes target discovery, validation and predictive discovery programs. Compugen drug programs find therapies to treat metastatic microsatellite stable colorectal cancer, platinum-resistant ovarian cancer, advanced and metastatic non-small cell lung cancer (NSCLC) and metastatic gastric cancer. It operates in Israel, the US and Canada. Compugen is headquartered in Holon, Tel Aviv, Israel.
For a complete picture of COM-701’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
